Cervical dysplasia is typically
associated with human papillomavirus (HPV) infection, smoking, and is more
common in women above age 30. However, cervical dysplasia is a preventable and
cervical screening tests are useful to diagnosis precancerous stage.
Statistics:
The global Cervical
Dysplasia Market is estimated to account for US$ 447.7 Mn in terms of value
by the end of 2019.
Global Cervical Dysplasia Market:
Drivers
Increasing investment in cervical
dysplasia is expected to propel growth of the global cervical dysplasia market
over the forecast period. For instance, in June 2020, Cel-Sci, a phase 3 cancer
immunotherapy company, raised approximately US$ 10 million through the exercise
of warrants.
Global Cervical Dysplasia Market:
Opportunities
Leveraging virtual space is
expected to offer lucrative growth opportunities for players in the global
cervical dysplasia market. Diagnosing cervical dysplasia in first world countries
such as the U.S. has minimized the death rate of cervical cancer. However,
logistics behind this diagnosis process is difficult to implement in developing
countries due to women from remote villages rarely return to the clinic for
follow-ups. Smartphone application is developed to provide a point-of-care
preliminary diagnosis. Ultimately, the application would screen samples
obtained and immediately provide a preliminary diagnosis
* The sample copy includes: Report Summary, Table of Contents,
Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/1486
Global Cervical Dysplasia Market:
Restraints
Low awareness of cervical
dysplasia in emerging economies is expected to hinder growth of the global
cervical dysplasia market. Majority of women in emerging economies still do not
have a clear understanding about cervical cancer screening tests and its early
detection. Additionally, in low-resource settings, effective screening
awareness programs have been difficult to implement, thereby increasing the cervical
cancer mortality rates.
Key Takeaways:
The global cervical dysplasia
market was valued at US$ 447.7 Mn in 2019 and is forecast to reach a value of
US$ 784.8 by 2027 at a CAGR of 7.3% between 2020 and 2027. Increasing
prevalence of cervical cancer is expected to drive the market growth during the
forecast period.
Diagnostic Test segment held
dominant position in the global cervical dysplasia market in 2019, accounting
for 86.8% share in terms of value, increasing technological advancement along
with product approvals is expected to assist the segment growth.
Market Trends
Adoption of AI for predictive
cancer is expected to propel growth of the global cervical dysplasia market
over the forecast period. For instance, in September 2020, Google Cloud
received a contract to supply Veterans Affairs hospitals and Defense Health
Agency treatment facilities with AI for predictive cancer and disease
diagnosis.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/cervical-dysplasia-diagnostic-market-1486
Moreover, development of advanced
diagnostic tools is also expected to aid in growth of the global cervical
dysplasia market. For instance, in June 2020, researchers from the Institute of
Advanced Study in Science and Technology, India, reported development of a
robust fully automated software-based solution using Pap smear images to detect
abnormal growth or development of tissues in the cervix — the lower part of the
uterus that connects to the vagina.
Global Cervical Dysplasia Market:
Competitive Landscape
Major players operating in the
global cervical dysplasia market include, F. Hoffmann La-Roche Ltd., QIAGEN
N.V., Becton, Dickinson and Company, OncoHealth Corporation, Quest Diagnostics,
Inc., Hologic, Inc., Abbott Laboratories, ASKA Pharmaceutical Co., Ltd.,
Asieris Pharmaceuticals, BetterLife Pharma Inc., and KinoPharma, Inc.
Global Cervical Dysplasia Market:
Key Developments
Major players in the global
cervical dysplasia market are focused on approval and launch of new products to
expand their product portfolio. For instance, in July 2020, Asieris
Pharmaceuticals, a China-based biotech company, received Clinical Trial Approval
(CTA) from China's National Medical Products Administration (NMPA) for the
global, multi-centered Phase III clinical trial of its photodynamic drug-device
combination product, APL-1702 (Cevira), which is being developed for the
non-surgical treatment of high-grade cervical dysplasia.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/1486
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment